Top

Published in:

01-07-2018 | Letter to the Editor (by invitation)

Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Authors: Rita Laiginhas, Marta Inês Silva, Manuel Sousa Falcão

Excerpt

Dear Editor, …

Laiginhas R, Silva MI, Rosas V et al (2018) Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol 256:83–89. https://doi.org/10.1007/s00417-017-3836-1 CrossRefPubMed

Shah SU, Maturi RK (2017) Therapeutic options in refractory diabetic macular oedema. Drugs 77:481–492. https://doi.org/10.1007/s40265-017-0704-6 CrossRefPubMed

Karst SG, Lammer J, Mitsch C et al (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256:49–58. https://doi.org/10.1007/s00417-017-3828-1 CrossRefPubMed

Campochiaro PA, Brown DM, Pearson A et al (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119:2125–2132. https://doi.org/10.1016/j.ophtha.2012.04.030 CrossRefPubMed

Shah CP, Heier JS (2016) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retin 47:836–839. https://doi.org/10.3928/23258160-20160901-06 CrossRef

Rahimy E, Shahlaee A, Khan MA et al (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118–27.e2. https://doi.org/10.1016/j.ajo.2015.12.030 CrossRefPubMed

Herbaut A, Fajnkuchen F, Qu-Knafo L et al (2017) Switching to aflibercept in diabetic macular edema not responding to ranibizumab and/or intravitreal dexamethasone implant. J Ophthalmol 2017:1–8. https://doi.org/10.1155/2017/8035013 CrossRef

Bahrami B, Hong T, Zhu M et al (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:1133–1140. https://doi.org/10.1007/s00417-017-3624-y CrossRefPubMed

Title: Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Authors: Rita Laiginhas
Marta Inês Silva
Manuel Sousa Falcão
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-3952-6